Our findings are further supported by in vivo animal studies, which showed that pyrotinib inhibited tumour growth and HER2 downstream pathways more effectively than pertuzumab in HER2-positive breast cancer cells with primary resistance to trastuzumab.12 Nevertheless, additional clinical trials are needed to validate these results. Here, ERBB2 is linked to neoplasm.